Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline

被引:85
作者
Doyle-Delgado, Kacie [1 ,2 ,6 ]
Chamberlain, James J. [1 ,2 ,6 ]
Shubrook, Jay H. [3 ]
Skolnik, Neil [4 ]
Trujillo, Jennifer [5 ]
机构
[1] St Marks Hosp, 1160 East 3900 South,Suite 1200, Salt Lake City, UT 84124 USA
[2] St Marks Diabet Ctr, Salt Lake City, UT 84124 USA
[3] Touro Univ Calif, Coll Osteopath Med, 1310 Club Dr, Vallejo, CA 94592 USA
[4] Abington Family Med, 500 Old York Rd,Suite 108, Jenkintown, PA 19046 USA
[5] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus,12850 East Montview Blvd, Aurora, CO 80045 USA
[6] St Marks Diabet Ctr, Internal Med St Marks, 1160 East 3900 South,Suite 1200, Salt Lake City, UT 84124 USA
关键词
GLARGINE; 100; U/ML; PEPTIDE-1 RECEPTOR AGONIST; ORAL ANTIHYPERGLYCEMIC DRUGS; TO-TARGET TRIAL; INSULIN GLARGINE; BASAL INSULIN; CARDIOVASCULAR OUTCOMES; COMBINATION THERAPY; GLUCOSE CONTROL; HEART-FAILURE;
D O I
10.7326/M20-2470
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Description: The American Diabetes Association (ADA) updates the Standards of Medical Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of diabetes. Methods: To develop the 2020 Standards, the ADA Professional Practice Committee, comprising physicians, adult and pediatric endocrinologists, diabetes educators, registered dietitians, epidemiologists, pharmacists, and public health experts, continuously searched MEDLINE (English language only) from 15 October 2018 through August-September 2019 for pertinent studies, including high-quality trials that addressed pharmaco-logic management of type 2 diabetes. The committee selected and reviewed the studies, developed the recommendations, and solicited feedback from the larger clinical community. Recommendations: This synopsis focuses on guidance relating to the pharmacologic treatment of adults with type 2 diabetes. Recommendations address oral and noninsulin injectable therapies, insulin treatment, and combination injectable therapies. Results of recent large trials with cardiovascular and renal outcomes are emphasized.
引用
收藏
页码:813 / +
页数:11
相关论文
共 64 条
[1]   A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients [J].
Abd El Aziz, Mirna S. ;
Kahle, Melanie ;
Meier, Juris J. ;
Nauck, Michael A. .
DIABETES OBESITY & METABOLISM, 2017, 19 (02) :216-227
[2]   Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial [J].
Abdul-Ghani, M. A. ;
Puckett, C. ;
Triplitt, C. ;
Maggs, D. ;
Adams, J. ;
Cersosimo, E. ;
DeFronzo, R. A. .
DIABETES OBESITY & METABOLISM, 2015, 17 (03) :268-275
[3]   Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study [J].
Akturk, Halis Kaan ;
Snell-Bergeon, Janet K. ;
Rewers, Amanda ;
Klaff, Leslie J. ;
Bode, Bruce W. ;
Peters, Anne L. ;
Bailey, Timothy S. ;
Garg, Satish K. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (10) :639-647
[4]   Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study [J].
Aroda, Vanita R. ;
Edelstein, Sharon L. ;
Goldberg, Ronald B. ;
Knowler, William C. ;
Marcovina, Santica M. ;
Orchard, Trevor J. ;
Bray, George A. ;
Schade, David S. ;
Temprosa, Marinella G. ;
White, Neil H. ;
Crandall, Jill P. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (04) :1754-1761
[5]   Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations [J].
Bennett, Wendy L. ;
Maruthur, Nisa M. ;
Singh, Sonal ;
Segal, Jodi B. ;
Wilson, Lisa M. ;
Chatterjee, Ranee ;
Marinopoulos, Spyridon S. ;
Puhan, Milo A. ;
Ranasinghe, Padmini ;
Block, Lauren ;
Nicholson, Wanda K. ;
Hutfless, Susan ;
Bass, Eric B. ;
Bolen, Shari .
ANNALS OF INTERNAL MEDICINE, 2011, 154 (09) :602-613
[6]   Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATETM study [J].
Blonde, L. ;
Merilainen, M. ;
Karwe, V. ;
Raskin, P. .
DIABETES OBESITY & METABOLISM, 2009, 11 (06) :623-631
[7]   Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial [J].
Bode, Bruce W. ;
McGill, Janet B. ;
Lorber, Daniel L. ;
Gross, Jorge L. ;
Chang, P. -C. ;
Bregman, David B. .
DIABETES CARE, 2015, 38 (12) :2266-2273
[8]   New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) [J].
Bolli, G. B. ;
Riddle, M. C. ;
Bergenstal, R. M. ;
Ziemen, M. ;
Sestakauskas, K. ;
Goyeau, H. ;
Home, P. D. .
DIABETES OBESITY & METABOLISM, 2015, 17 (04) :386-394
[9]   Insulin Access and Affordability Working Group: Conclusions and Recommendations [J].
Cefalu, William T. ;
Dawes, Daniel E. ;
Gavlak, Gina ;
Goldman, Dana ;
Herman, William H. ;
Van Nuys, Karen ;
Powers, Alvin C. ;
Taylor, Simeon I. ;
Yatvin, Alan L. .
DIABETES CARE, 2018, 41 (06) :1299-1311
[10]   Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes [J].
Diamant, Michaela ;
Nauck, Michael A. ;
Shaginian, Rimma ;
Malone, James K. ;
Cleall, Simon ;
Reaney, Matthew ;
de Vries, Danielle ;
Hoogwerf, Byron J. ;
MacConell, Leigh ;
Wolffenbuttel, Bruce H. R. .
DIABETES CARE, 2014, 37 (10) :2763-2773